Payer & Reimbursement Stakeholders
Insurance payers, reimbursement specialists, and coverage strategists working to make psychedelic therapy financially accessible.
All Organisations
Federal Joint Committee (G-BA)
Germany’s highest decision-making body in joint self-government that issues binding reimbursement and benefit-assessment resolutions, including esketamine-related AMNOG outcomes.
Institute for Clinical and Economic Review (ICER)
U.S. value assessment organization that publishes comparative effectiveness and cost-effectiveness reports used by payers and policymakers, including assessments relevant to esketamine.
Pharmaceutical Benefits Advisory Committee (PBAC)
Australian committee that evaluates comparative clinical and cost-effectiveness evidence to advise PBS reimbursement decisions, including medicine status updates for esketamine.
pan-Canadian Pharmaceutical Alliance (pCPA)
Canadian pan-jurisdictional payer negotiation body that coordinates joint drug price negotiations for public plans, including completed negotiations for Spravato (esketamine).